According to recent market data tezspire tezepelumab had a 7 1 share of paid biologic prescriptions trx in the u's from may 2023 to april 2024?

I can’t confirm that exact figure without seeing the source data. If you have a link or citation for that market data (May 2023–April 2024, US, paid TRx, tezepelumab/Tezspire), share it and I’ll summarize or interpret it.

What I can say in general:
- Tezspire (tezepelumab) is a newer biologic for severe asthma and has been gaining share in the US asthma biologics market, but it competes with established agents like Dupixent (dupilumab), Nucala (mepolizumab), and Fasenra (benralizumab).
- “Paid TRx” refers to prescriptions that insurers actually paid for, which can differ from total prescriptions due to patient assistance programs, rebates, or mix of payer types.
- A 7.1% share would indicate a meaningful but not dominant position in the US paid TRx base for biologic asthma therapies during that window.

If you want, I can:
- Explain how to interpret TRx share and how it differs from market share by revenue.
- Help locate the specific source and extract the key numbers (source validity, timeframe, and any caveats).
- Compare tezepelumab’s share to other biologics over that period if you provide or I can access the data.